Echocardiographic measurement of epicardial adipose tissue thickness in patients with microvascular angina

MACİT KALÇIK1,*, MAHMUT YEŞİN2, AHMET GÜNER3, EMRAH BAYAM4, MUCAHİT YETİM1, TOLGA DOĞAN1, LÜTFÜ BEKAR1, ÖĞUZHAN ÇELİK5, YUSUF KARAVELİOĞLU1

1Faculty of Medicine, Department of Cardiology, Hitit University, Çorum, Turkey
2Department of Cardiology, Kars Harakanı State Hospital, Kars, Turkey
3Department of Cardiology, Kosuyolu Kartal Training and Research Hospital, Istanbul, Turkey
4Department of Cardiology, Umranıye Training and Research Hospital, İstanbul, Turkey
5Department of Cardiology, Muğla Sıtkı Koçman University Training and Research Hospital, Muğla, Turkey

*Corresponding author: Macit Kalçık, MD; Faculty of Medicine, Department of Cardiology, Hitit University, Buharaevler Mah. Buhara 25. Sok. No:1/A, Daire: 22, Çorum, Turkey; Phone: +90 536 492 17 89; Fax: +90 364 511 78 89; E-mail: macitkalcik@yahoo.com

(Received: April 3, 2019; Revised manuscript received: April 12, 2019; Accepted: April 16, 2019)

Abstract: Introduction: Impaired coronary microcirculation, inflammation, and endothelial dysfunction were reported etiological factors for microvascular angina (MVA). Recently, increased epicardial adipose tissue (EAT) thickness has been associated with hypertension, metabolic syndrome, and coronary artery disease in general population. In this study, we aimed to evaluate the EAT thickness in patients with MVA. Methods: This study enrolled 200 patients (83 males; mean age: 55.4 ± 8.2 years) who have been diagnosed with MVA and 200 controls (89 males; mean age: 54.4 ± 8.5 years). All patients underwent transthoracic echocardiography, and EAT thickness was measured from a parasternal long-axis view as the hypoechoic space on the right ventricular free wall. Results: The mean EAT thickness was significantly higher in MVA patients than the controls (5.5 ± 1.1 vs. 4.9 ± 0.7 mm; p < 0.001). Multiple logistic regression analysis showed that increased EAT thickness was an independent predictor of MVA (OR = 1.183, 95% CI = 1.063–1.489; p = 0.023). In receiver operating characteristic curve analyses, EAT thickness above 5.3 mm predicted MVA with a sensitivity of 68% and a specificity of 63% (AUC = 0.711, 95% CI = 0.659–0.762; p < 0.001). Conclusions: The EAT thickness was observed significantly higher in MVA patients as compared to controls. Increased EAT thickness may be associated with mechanisms that play a major role in the pathogenesis of MVA.

Keywords: coronary angiography, coronary artery disease, echocardiography, epicardial adipose tissue thickness, microvascular angina

Introduction

Coronary angiography may reveal normal coronary arteries in a significant proportion (20%–30%) of patients presenting with typical angina pectoris [1]. Although non-cardiac causes may be responsible for the chest pain, a considerable subset of these patients have true angina due to myocardial ischemia in the absence of angiographically significant coronary stenosis [2]. The term microvascular angina (MVA) is used to describe patients with typical angina pectoris and a positive stress test (classic downsloping ST segment depression on treadmill exercise test, and/or a reversible perfusion defect on radionuclide myocardial perfusion scan), in the absence of significant coronary stenosis on angiography and other cardiac diseases [3]. Coronary microvascular dysfunction was suggested to be the underlying pathophysiologic mechanism. Moreover, endothelial dysfunction with subsequent microvascular ischemia has been implicated as an important contributing factor [4]. Although several studies reported that patients with MVA supposed to have excellent long-term clinical outcome [5], other clinical reports have been reported that...
Epicardial adipose tissue (EAT) is a true visceral fat tissue, deposited in proximity to the atrium, the right ventricle’s free wall, and left ventricular apex of the heart [7]. Under normal conditions, EAT has important functions, such as protecting vascular functions and providing energy requirement of the heart by producing free fatty acids, which are energy sources for myocardium. However, when volume of the EAT increases, this tissue acquires a prothrombotic and proinflammatory characteristics [8]. Increased EAT thickness has been defined as a cardiometabolic risk factor with a possible role in the pathogenesis of cardiovascular diseases, such as hypertension, insulin resistance, metabolic syndrome, and coronary artery disease [9]. However, the role of increased EAT thickness in patients with MVA has not been investigated yet.

In this study, we aimed to investigate the possible role of increased EAT thickness in the pathogenesis of MVA.

Methods

Study population

A total of 200 patients (83 males; mean age: 55.4 ± 8.2 years) who have been diagnosed with MVA and 200 controls (89 males; mean age: 54.4 ± 8.5 years) were enrolled in this single-center case–control study between May 2016 and January 2019. Patients with moderate to severe left ventricular systolic dysfunction, end-stage liver disease, renal insufficiency, chronic inflammatory diseases, connective tissue diseases, and malignancies were excluded from the study. Patients who had angina pectoris with detectable ischemia on non-invasive tests, such as treadmill stress test or myocardial perfusion scintigraphy and without any evidence of stenosis or vasospasm of epicardial coronary arteries during invasive coronary angiography were diagnosed as MVA. Age- and sex-matched asymptomatic controls without any detectable ischemia on non-invasive tests constituted the control group. All patients underwent transthoracic echocardiography (TTE). Complete blood count and blood chemistry panel were measured in all patients during admission. All demographic, laboratory, and echocardiographic parameters were recorded into a data set and compared between MVA patients and controls. All patients provided a written informed consent and the study protocol was approved by the local ethics committee of the Kosuyolu Kartal Training and Research Hospital in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

Laboratory analysis

In order to perform complete blood count and blood chemistry panel, venous blood samples were collected after 12 h of fasting by a clean puncture of an antecubital vein from all patients. Complete blood countings were measured on Sysmex XT2000i analyzer (Sysmex Corporation, Kobe, Japan). Fasting blood glucose, blood urea nitrogen, creatinine, uric acid, total bilirubin, alanine aminotransferase, aspartate aminotransferase, total cholesterol (TC), high-density lipoprotein (HDL), and triglyceride (TG) levels were also measured on an autoanalyzer (Siemens Advia 2400 Chemistry System, Siemens Diagnostic, Tarrytown, NY, USA). Low-density lipoprotein (LDL) was calculated using the Friedewald formula: LDL (mg/dl) = TC – (HDL + TG/5) [10].

Echocardiography

All patients underwent TTE performed by the same cardiologist using Vivid 5 echocardiography device (GE Vingmed Ultrasound AS, Horten, Norway) and 3.2 mHz adult probe with the patient in the left lateral decubitus position. In all patients, the left ventricular posterior wall thickness (PWT), interventricular septal thickness (IVST), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and left atrial diameter (LAD) were measured on the parasternal long-axis view. The early diastolic peak flow velocity (E wave) and the late diastolic peak flow velocity (A wave) were measured using a color-guided pulsed Doppler echocardiographic examination. Left ventricular ejection fractions (LVEFs) of the patients were calculated using biplane Simpson’s method.

Measurement of EAT thickness

The measurement of EAT thickness was performed by TTE from a parasternal long-axis view on the right ventricle’s free wall at end-diastole, and the greatest perpendicular distance to the aortic annulus was achieved and averaged over three cardiac cycles [11]. In parasternal long-axis window, hypoechic space on the right ventricular free wall was defined as EAT (Fig. 1).

Statistical analyses

Statistical analyses were performed using IBM SPSS Statistics for Windows, version 19.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were reported as mean ± standard deviation for continuous variables with normal distribution or median (25th–75th percentiles) values for continuous variables without normal distribution and as frequency with percentages for the categorical variables. The Shapiro–Wilk and Kolmogorov–Smirnov tests were used to test the normality of the distribution of continuous variables. Categorical variables were
The univariate parameters, which were possible predictors of MVA, were taken into multiple logistic regression analysis. Increased EAT thickness was an independent predictor of MVA (odds ratio = 1.183, 95% CI = 1.063–1.489; \( p = 0.023 \) (Table II). In the ROC curve analysis, EAT thickness above 5.3 mm predicted MVA with a sensitivity of 69% and a specificity of 64% (AUC = 0.711, 95% CI = 0.659–0.762; \( p < 0.001 \) (Fig. 2B).

Discussion

In this observational case-control study, we have focused on the role of increased EAT thickness in patients with MVA. The EAT thickness was observed significantly higher in MVA patients as compared to controls with similar cardiovascular risk factors. These results support that increased EAT thickness may be associated with mechanisms, which play a major role in the pathogenesis of MVA.

Epicardial coronary artery stenosis is usually responsible for myocardial ischemia. However, with the technical advancements in the past 30 years, studies have shown that abnormalities in coronary microcirculation may also cause myocardial ischemia in patients with normal coronary arteries [12]. In 1973, Kemp [13] first described these patients as having MVA, defined as typical angina pectoris with abnormal stress test results indicative of myocardial ischemia and normal coronary arteries on coronary angiography. Since the original description of coronary syndrome X over 30 years ago, a large number of studies have focused on establishing an ischemic origin for this condition. The pathophysiology of MVA is multifactorial and endothelial dysfunction with subsequent microvascular ischemia has been implicated as an important contributing factor [4].

EAT located beneath the visceral pericardium is a particular variety of visceral fat tissue. The physiological, biochemical, and biomolecular properties of EAT and the possible paracrine reactions have been reported in previous studies [14]. Various studies have highlighted the potential importance of EAT in relation to inflammatory burden in cardiovascular diseases, such as coronary artery disease [15], subclinical atherosclerosis [16], and metabolic syndrome [11]. The EAT has been reported to have high capacity of local proinflammatory activity [17]. There is growing evidence that the changes in perivascular tissues surrounding epicardial coronary arteries could alter vascular homeostasis and contribute to endothelial dysfunction, amplification of vascular inflammation, intimal lesions, and plaque progression by an outside-to-inside signaling mechanism [18, 19].

The EAT is present over the base of the heart, the atrioventricular groove, bases of great vessels, along the distribution of coronary arteries, over the right
ventricle especially over the free wall and at the apex. Coronary arteries and their epicardial branches are embedded in the EAT [20]. Under physiological conditions, EAT functions in the maintenance of fatty acid homeostasis for the local vascular bed and has higher lipogenetic and lipolytic activity than other fat tissues [21]. Simultaneously, EAT is a well-known source of adipokines including a wide range of inflammatory mediators to a larger extent than the subcutaneous and omental fat [22] and secretes vasoactive products that

| Table I | The comparison of demographic, echocardiographic, and laboratory parameters between patient and control groups |
|---------|-------------------------------------------------------------------------------------------------------------|
| Demographic parameters |                                                                                                             |
| Age (years) | MVA (n = 200) 55.4 ± 8.2 | Controls (n = 200) 54.4 ± 8.5 | 0.231 |
| Gender: male [n (%)] | MVA 83 (41.5) | Controls 89 (44.5) | 0.545 |
| BMI (kg/m²) | MVA 29.3 (25.1–31.5) | Controls 28.9 (26.2–31.8) | 0.874 |
| SBP (mmHg) | MVA 138.2 ± 16.3 | Controls 134.5 ± 11.4 | 0.475 |
| DBP (mmHg) | MVA 83.6 ± 9.3 | Controls 82.5 ± 10.3 | 0.674 |
| Heart rate (beats/min) | MVA 77.5 ± 11.3 | Controls 74.6 ± 10.4 | 0.124 |
| Hypertension [n (%)] | MVA 66 (33) | Controls 54 (27) | 0.190 |
| Diabetes mellitus [n (%)] | MVA 41 (20.5) | Controls 36 (18) | 0.526 |
| Dyslipidemia [n (%)] | MVA 44 (22) | Controls 55 (27.5) | 0.203 |
| Smoking status [n (%)] | MVA 50 (25) | Controls 46 (23) | 0.640 |
| Echocardiographic parameters |                                                                                                             |
| LVEF (%) | MVA 64.7 ± 5.1 | Controls 65.6 ± 4.3 | 0.421 |
| LAD (mm) | MVA 38 (35.7–40.2) | Controls 38 (36.7–40.5) | 0.579 |
| LVEDD (cm) | MVA 4.5 (4.3–4.9) | Controls 4.3 (4.2–4.8) | 0.312 |
| LVESD (cm) | MVA 2.96 ± 0.65 | Controls 2.93 ± 0.53 | 0.788 |
| IVST (mm) | MVA 11 (11–12) | Controls 11 (11–12) | 0.178 |
| PWT (mm) | MVA 11 (11–12) | Controls 11 (11–12) | 0.751 |
| E (cm/s) | MVA 0.6 (0.5–0.7) | Controls 0.7 (0.5–0.9) | 0.378 |
| A (cm/s) | MVA 1 (0.8–1) | Controls 0.95 (0.7–1) | 0.266 |
| Laboratory parameters |                                                                                                             |
| Glucose (mg/dl) | MVA 94.8 ± 11.2 | Controls 96.3 ± 9.8 | 0.742 |
| BUN (g/dl) | MVA 28.4 ± 9.9 | Controls 33.1 ± 10.3 | 0.492 |
| Creatinine (g/dl) | MVA 0.83 ± 0.19 | Controls 0.79 ± 0.17 | 0.316 |
| AST (U/L) | MVA 21.5 (17–26.25) | Controls 20.5 (18.25–24) | 0.521 |
| ALT (U/L) | MVA 19.5 (13.75–24.25) | Controls 18.5 (15.5–23.5) | 0.613 |
| Uric acid (mg/dl) | MVA 4.92 ± 1.0 | Controls 4.81 ± 1.0 | 0.766 |
| Total bilirubin (mg/dl) | MVA 0.6 (0.4–0.9) | Controls 0.7 (0.5–0.8) | 0.697 |
| LDL (mg/dl) | MVA 128.9 ± 25.8 | Controls 134.9 ± 33.7 | 0.345 |
| HDL (mg/dl) | MVA 42 (34–48) | Controls 44 (36–52) | 0.328 |
| Triglycerides (mg/dl) | MVA 166.5 ± 89.4 | Controls 169.3 ± 81.7 | 0.756 |
| Total cholesterol (mg/dl) | MVA 189.6 ± 27.8 | Controls 201.8 ± 41.6 | 0.362 |
| Hemoglobin (g/dl) | MVA 13.9 ± 1.6 | Controls 14.1 ± 1.9 | 0.817 |
| White blood cell (×10³/dl) | MVA 7.9 ± 1.8 | Controls 8.3 ± 1.9 | 0.325 |
| Platelet (×10³/dl) | MVA 239.8 ± 45.6 | Controls 243.1 ± 51.6 | 0.741 |

MVA: microvascular angina; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LVEF: left ventricular ejection fraction; LAD: left atrial diameter; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; IVST: interventricular septal thickness; PWT: posterior wall thickness; E: atrial E wave; A: atrial A wave; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDL: low-density lipoprotein; HDL: high-density lipoprotein
regulate coronary arterial tone [23]. It has also been shown that periadventitial application of inflammatory mediators induces inflammatory cell influx into the arterial wall, coronary vasospasm, and intimal lesions [19]. Thus, inflammatory mediators secreted by the EAT surrounding coronary arteries may lead to impaired coronary blood flow reserve through an outside-to-inside cellular cross-talk. Lack of any fascia between the adipocytes and myocardium allows these direct interactions of vascular bed and the surrounding EAT [14]. Supported by the previous studies, increased EAT thickness may be associated with local and paracrine mechanisms that play role in the pathogenesis of MVA.

### Study limitations

The primary limitation was that this study was a non-randomized and single-center study with a relatively small number of patients. Second, coronary angiography was not performed in the control group; this issue is also open to criticism. A control group without symptoms and with a negative stress test and angiographically normal coronary arteries would have been ideal. However, it would be impossible to get approval from the ethics committee to perform coronary angiography in a patient group without symptoms and with a negative stress test in our country. Finally, magnetic resonance imaging (MRI), which was known as the gold standard for the measurement of EAT, was not used in this study. However, the widespread use of MRI is not practical for a screening parameter, and echocardiography has been validated against MRI for quantitative assessment of EAT [11].

### Conclusions

The EAT thicknesses were observed significantly higher in MVA patients as compared to controls with similar cardiovascular risk factors. Increased EAT thickness may be associated with mechanisms that play a major role in the pathogenesis of MVA. Echocardiographic measurement of EAT thickness may be an additional and easy diagnostic tool for risk stratification of patients with
Epicardial adipose tissue and microvascular angina

1. Melikian N, De Bruyne B, Fearon WF, MacCarthy PA: The pathophysiology and clinical course of the normal coronary angina syndrome (cardiac syndrome X). Prog Cardiovasc Dis 50, 294–310 (2008)

2. Phan A, Shufelt C, Merz CN: Persistent chest pain and no obstructive coronary artery disease. JAMA 301, 1468–1474 (2009)

3. Singh M, Singh S, Arora R, Khosla S: Cardiac syndrome X: Current concepts. Int J Cardiol 142, 113–119 (2010)

4. Hurst T, Olson TH, Olson LE, Appleton CP: Cardiac syndrome X and endothelial dysfunction: New concepts in prognosis and treatment. Am J Med 119, 560–566 (2006)

5. Cannon RO: Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol 54, 877–885 (2009)

6. Chen C, Wei J, AlBadri A, Zarrini P, Baiery Merz CN: Coronary microvascular dysfunction – Epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy. Circ J 81, 3–11 (2016)

7. Schejbal V: Epicardial fatty tissue of the right ventricle morphology, microvascularity and functional significance. Pneumologie 43, 489–499 (1999)

8. Iozzo P: Myocardial, perivascular, and epicardial fat. Diabetes Care 34, S371–S379 (2011)

9. Iacobellis G, Willems HJ: Echocardiographic epicardial fat: A review of research and clinical applications. J Am Soc Echocardiogr 22, 1311–1319 (2009)

10. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499–502 (1972)

11. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F: Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: A new indicator of cardiovascular risk. J Clin Endocrinol Metab 88, 5163–5168 (2003)

12. Lanza GA, Crea F: Primary coronary microvascular dysfunction clinical presentation, pathophysiology, and management. Circulation 121, 2317–2325 (2010)

13. Kemp HG: Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. Am J Cardiol 32, 375–376 (1973)

14. Iacobellis G, Corradi D, Sharma AM: Epicardial adipose tissue: Anatomic, biologic and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2, 536–543 (2005)

15. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, O’Donnell CJ, Fox CS: Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: The Framingham Heart Study. Circulation 117, 605–613 (2008)

16. Iacobellis G, Pellicelli AM, Sharma AM, Grisòrio B, Barbarini G, Barbaro G: Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol 99, 1470–1472 (2007)

17. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y: Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108, 2460–2466 (2003)

18. Miyata K, Shimokawa H, Kandabashi T, Higo T, Morahige K, Eto Y, Egashira K, Kaibuchi K, Takeshita A: Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20, 2351–2358 (2000)

19. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, Takayanagi T, Egashira K, Takeshita A: Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 97, 769–776 (1996)

20. Rabin SW: Epicardial fat: Properties, function and relationship to obesity. Obes Rev 8, 253–261 (2007)

21. Marchington JM, Mattacks CA, Pond CM: Adipose tissue in the mammalian heart and pericardium: Structure, foetal development and biochemical properties. Comp Biochem Physiol B 94, 225–232 (1989)

22. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Alhauad G, Teboul M, Massiera F, Sharma AM: The adipose-tissue renin-angiotensinaldosterone system: Role in the metabolic syndrome? Int J Biochem Cell Biol 35, 807–825 (2003)

23. Sacks HS, Fain JN: Human epicardial adipose tissue: A review. Am Heart J 153, 907–917 (2007)